Literature DB >> 7730327

Alternately spliced NH2-terminal immunoglobulin-like Loop I in the ectodomain of the fibroblast growth factor (FGF) receptor 1 lowers affinity for both heparin and FGF-1.

F Wang1, M Kan, G Yan, J Xu, W L McKeehan.   

Abstract

Alternate splicing of a single exon encoding an NH2-terminal immunoglobulin (Ig) disulfide loop in the ectodomain of the fibroblast growth factor receptor (FGFR) types 1 and 2 results in alpha and beta isoforms that exhibit 3- and 2-Ig loops, respectively. Previously we demonstrated that alternately spliced Loop I has no independent ligand binding activity but is sufficiently interactive with the ligand- and heparin-binding site formed by Loops II and III to lower affinity for the same fibroblast growth factor (FGF) ligand. Here we show that a lower affinity of FGFR1 alpha for heparin parallels the lower affinity for FGF-1. A mutant of FGFR1 alpha in which the sequence between Loops I and II was deleted exhibits high affinity for both FGF-1 and heparin and other properties of the FGFR1 beta isoform, which include resistance to degradation by trypsin and display of specific antibody epitopes. This suggests that the interloop sequence facilitates the interaction of Loop I with Loops II and III. Lack of expression of both exons coding for Loop I and the sequence between Loops I and II in the FGFR2 gene characterizes rat prostate tumor cells, which exhibit a loss of the low affinity class of FGF receptors. Although the exon coding for the sequence between Loops I and II is alternately spliced in the FGFR2 beta isoform, coordinate expression with the exon coding for Loop I results in the functional differences between the FGFR alpha and FGFR beta variants.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7730327     DOI: 10.1074/jbc.270.17.10231

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  40 in total

1.  Molecular characteristics of fibroblast growth factor-fibroblast growth factor receptor-heparin-like glycosaminoglycan complex.

Authors:  G Venkataraman; R Raman; V Sasisekharan; R Sasisekharan
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

2.  Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity.

Authors:  Shaun K Olsen; Omar A Ibrahimi; Angela Raucci; Fuming Zhang; Anna V Eliseenkova; Avner Yayon; Claudio Basilico; Robert J Linhardt; Joseph Schlessinger; Moosa Mohammadi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-19       Impact factor: 11.205

3.  Analysis of mutations in fibroblast growth factor (FGF) and a pathogenic mutation in FGF receptor (FGFR) provides direct evidence for the symmetric two-end model for FGFR dimerization.

Authors:  Omar A Ibrahimi; Brian K Yeh; Anna V Eliseenkova; Fuming Zhang; Shaun K Olsen; Makoto Igarashi; Stuart A Aaronson; Robert J Linhardt; Moosa Mohammadi
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

Review 4.  An essential role for FGF receptor signaling in lens development.

Authors:  Michael L Robinson
Journal:  Semin Cell Dev Biol       Date:  2006-10-27       Impact factor: 7.727

5.  NMR structure of the first Ig module of mouse FGFR1.

Authors:  Vladislav V Kiselyov; Elisabeth Bock; Vladimir Berezin; Flemming M Poulsen
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

6.  Elucidation of the mechanism of the regulatory function of the Ig1 module of the fibroblast growth factor receptor 1.

Authors:  Vladislav V Kiselyov; Arthur Kochoyan; Flemming M Poulsen; Elisabeth Bock; Vladimir Berezin
Journal:  Protein Sci       Date:  2006-10       Impact factor: 6.725

7.  Functions of the ectodomain and cytoplasmic tyrosine phosphatase domains of receptor protein tyrosine phosphatase Dlar in vivo.

Authors:  Neil X Krueger; R Sreekantha Reddy; Karl Johnson; Jack Bateman; Nancy Kaufmann; Daniella Scalice; David Van Vactor; Haruo Saito
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

Review 8.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

9.  Ligand activation of alternatively spliced fibroblast growth factor receptor-1 modulates pancreatic adenocarcinoma cell malignancy.

Authors:  Selwyn M Vickers; Zhi-Qiang Huang; LeeAnn MacMillan-Crow; Jessica S Greendorfer; John A Thompson
Journal:  J Gastrointest Surg       Date:  2002 Jul-Aug       Impact factor: 3.452

Review 10.  Therapeutic potential of manipulating VEGF splice isoforms in oncology.

Authors:  Emma S Rennel; Steven J Harper; David O Bates
Journal:  Future Oncol       Date:  2009-06       Impact factor: 3.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.